¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Global Forecast 2025-2030
»óǰÄÚµå : 1585674
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 194 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹ÙÀÌ¿À½Ã¹Ð·¯(Biosimilars) ½ÃÀåÀº 2023³â¿¡ 407¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 499¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, CAGR 23.31%·Î ÃßÀÌÇÏ¸ç ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 1,764¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ¹Ì Çã°¡µÈ ÂüÁ¶ Á¦Ç°°ú ¸Å¿ì À¯»çÇÑ »ý¹°ÇÐÀû ÀÇ·á Á¦Ç°ÀÎ ¹ÙÀÌ¿À½Ã¹Ð·¯´Â °í°¡ÀÇ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ¸·Î ÀÎÇØ Á¦¾à »ê¾÷¿¡¼­ ÇÙ½ÉÀûÀÎ ºÎ¹®À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ Çʿ伺Àº ÀÇ·á ºñ¿ëÀÇ Áõ°¡¿Í ¿À¸®Áö³Î »ý¹°ÇÐÀû Á¦Á¦ÀÇ Æ¯Çã ¸¸·á·Î ÀÎÇØ ¾Ï, ´ç´¢º´, ÀÚ°¡ ¸é¿ª Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â Àú·ÅÇÑ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹ß»ýÇÕ´Ï´Ù. Á¾¾çÇÐ, ¸é¿ªÇÐ, ³»ºÐºñÇÐ µî ´Ù¾çÇÑ Ä¡·á ºÐ¾ß¿¡ °ÉÃÄ Àû¿ëµÇ°í ÀÖÀ¸¸ç ÃÖÁ¾ »ç¿ëÀÚ ¹üÀ§´Â º´¿ø, Ŭ¸®´Ð, ¿¬±¸ ±â°üÀ¸·Î È®ÀåµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀº ¸¸¼º ÁúȯÀÇ ¹ß»ý·ü Áõ°¡, ±ÔÁ¦ Áö¿ø, ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼ö¿ë Áõ°¡¿Í °°Àº ¿äÀο¡ Å©°Ô ¿µÇâÀ» ¹Þ½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï ½ÃÀå°ú Á¦Á¶ °øÁ¤ÀÇ ±â¼ú ¹ßÀüÀº »ó´çÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±â¾÷Àº ¹ÙÀÌ¿À½Ã¹Ð·¯ äÅ÷üÀ» ³ôÀÌ°í ½ÃÀå ¹üÀ§¸¦ È®´ëÇϱâ À§ÇØ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿ÍÀÇ Àü·«Àû Çù¾÷°ú °ø°ÝÀûÀÎ ¸¶ÄÉÆÃ Àü·«¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ÁöÀû Àç»ê±ÇÀÇ º¹À⼺, ÂüÁ¶ »ý¹°ÇÐÀû Á¦Á¦¿ÍÀÇ À¯»ç¼ºÀ» ÀÔÁõÇϱâ À§ÇÑ ±¤¹üÀ§ÇÑ ÀÓ»ó½ÃÇèÀÇ Çʿ伺 µî ¿©ÀüÈ÷ °úÁ¦°¡ ³²¾Æ ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ÇѰè´Â ¿À¸®Áö³Î »ý¹°ÇÐÀû Á¦Á¦¿¡ ºñÇØ È¿´É°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á°¡ Áö¼ÓµÇ¾î ¹ÙÀÌ¿À½Ã¹Ð·¯ ó¹æÀ» ÁÖÀúÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°¿¡µµ ºÒ±¸ÇÏ°í ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ß ÇÁ·Î¼¼½º °³¼±, ¾à¹°°¨½Ã ½Ã½ºÅÛ °­È­, °ø±Þ¸Á È¿À²¼º ÃÖÀûÈ­ µî ÀÌ ºÐ¾ß´Â Çõ½ÅÀ» À§ÇÑ Ç³ºÎÇÑ ±æÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ±â¾÷Àº ¾à±¹ ¼öÁØ¿¡¼­ ÀÚµ¿ ´ëü·Î À̾îÁú ¼ö ÀÖ´Â »óÈ£ ±³È¯ °¡´ÉÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Çü °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸¿¡ ÅõÀÚÇÏ¿© ½ÃÀå ħÅõÀ²À» ³ô¿©¾ß ÇÕ´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº ƯÇã ¸¸·á¿Í ³ôÀº ¿¬±¸ °³¹ß ÅõÀÚ·Î ÀÎÇÑ Ä¡¿­ÇÑ °æÀïÀÌ Æ¯Â¡À̸ç, ¾Õ¼­ ³ª°¡·Á¸é Àü ¼¼°èÀûÀ¸·Î ±ÞÁõÇÏ´Â »ý¹°ÇÐÀû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Ȱ¿ëÇϱâ À§ÇØ Áö¼ÓÀûÀÎ Çõ½Å°ú ÀûÀÀÇü ¸¶ÄÉÆÃ Àü·«ÀÌ ÇÊ¿äÇÔÀ» ½Ã»çÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ¿¬µµ(2023³â) 407¾ï ´Þ·¯
ÃßÁ¤¿¬µµ(2024³â) 499¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø¿¬µµ(2030³â) 1,764¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 23.31%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ ÁÖ¿ä ÀλçÀÌÆ® °ø°³

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°Í Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces : ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº ÀÚ½ÅÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÔÀ¸·Î½á º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ý·üÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®È­Çϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : Á¦Ç°º°

Á¦7Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ÀûÀÀÁõº°

Á¦8Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : Á¦Á¶º°

Á¦9Àå ¾Æ¸Þ¸®Ä« ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå

Á¦10Àå ¾Æ½Ã¾Æ ÅÂÆò¾çÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå

Á¦12Àå °æÀï ±¸µµ

±â¾÷ ¸ñ·Ï

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Biosimilars Market was valued at USD 40.70 billion in 2023, expected to reach USD 49.91 billion in 2024, and is projected to grow at a CAGR of 23.31%, to USD 176.48 billion by 2030.

Biosimilars, biologic medical products highly similar to already authorized reference products, represent a key segment within the pharmaceutical industry due to their potential to offer cost-effective alternatives to expensive biologics. The necessity for biosimilars arises from increasing healthcare costs and patent expirations of original biologics, driving demand for affordable therapies in treating chronic diseases like cancer, diabetes, and autoimmune disorders. Their applications span across various therapeutic areas, including oncology, immunology, and endocrinology, with end-user scope extending to hospitals, clinics, and research institutes. Market growth is heavily influenced by factors such as rising incidences of chronic diseases, regulatory support, and healthcare providers' growing acceptance of biosimilars. Moreover, emerging markets and technological advancements in manufacturing processes present substantial opportunities. Businesses should focus on strategic collaborations with healthcare providers and aggressive marketing strategies to enhance biosimilar adoption and expand market reach. However, challenges persist, including stringent regulatory requirements, intellectual property complexities, and the need for extensive clinical trials to establish similarity to reference biologics. Another limitation is the hesitancy in prescribing biosimilars due to lingering concerns regarding efficacy and safety compared to original biologics. Despite these hurdles, the sector holds rich avenues for innovation, particularly in improving biosimilar development processes, enhancing pharmacovigilance systems, and optimizing supply chain efficiencies. Companies should invest in research focused on improving interchangeable biosimilar formulations, which can lead to automatic substitution at the pharmacy level, thereby increasing market penetration. The biosimilars market is characterized by intense competition driven by patent expirations and high research and development investments, suggesting that staying ahead necessitates continuous innovation and adaptive marketing strategies to capitalize on burgeoning global demand for biologic treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 40.70 billion
Estimated Year [2024] USD 49.91 billion
Forecast Year [2030] USD 176.48 billion
CAGR (%) 23.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biosimilars Market

The Biosimilars Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Biosimilars Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biosimilars Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biosimilars Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biosimilars Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biosimilars Market

A detailed market share analysis in the Biosimilars Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biosimilars Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biosimilars Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biosimilars Market

A strategic analysis of the Biosimilars Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Biosimilars Market, by Product

7. Biosimilars Market, by Indication

8. Biosimilars Market, by Manufacturing

9. Americas Biosimilars Market

10. Asia-Pacific Biosimilars Market

11. Europe, Middle East & Africa Biosimilars Market

12. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â